Categories: New Launches

On World Diabetes Day- Medlife, India’s largest online e-pharmacy launches first of its kind diabetic footwear

The range of footwear has been designed to provide added protection against abrasions and ulcerations commonly seen in diabetic patients

Mumbai, November 15, 2018: Medlife, India’s largest online e-pharmacy company, has announced the launch of specialised Medlife Diabetic Footwear for diabetes patients and an array of services in a bid to encourage consumers to:

  1. a)Get themselves tested for diabetes
  2. b)Aid diabetic patients in managing their disease better

Foot problems are common in people with diabetes. Over time, diabetes may cause nerve damage also known as diabetic neuropathy, that can cause tingling and pain, and can make you lose sensation in your feet. Diabetes can also lower the amount of blood flow in your feet, making it difficult for a sore or an infection to heal. The diabetic footwear is specially designed to provide comfort in diabetic foot, while also addressing other foot ailments like arch pain, arthritis, hammertoes and heel pain. Apart from this, the pair of footwear also helps offload pressure from stress areas, is lightweight, and durable, provides cushioning for motion comfort and helps correct deformities. Medlife is also currently offering a Diabetes Screening test at 70% off. The screening package offers 54 vital tests that evaluate important parameters like HbA1c, creatinine, CBC, Complete Urine Analysis, Lipid Profile and more.

These efforts are in line with Medlife’s aim to launch a holistic drive against diabetes, spanning prevention, testing and treatment. For prevention, Medlife has introduced a product called Diabetasafe, a Diabetologist recommended 100% natural and herbal formulation that works effectively to combat the root causes of diabetes. The product is available as part of Medlife Essentials, an initiative by Medlife.com that offers a complete line of dietary supplements that prevent or manage diseases that are prevalent today.

The number of people with diabetes in India has gone up from 26 million in 1990 to 65 million in 2016. Furthermore, the jump in the rate of healthy years lost to diabetes since 1990 is the highest among major non-communicable diseases in India[i].

Mr. Tushar Kumar, CEO, Medlife said, “We at Medlife believe in using technology and innovation to better lives. Given the huge incidence of diabetes in India, we felt it is imperative to offer consumers an opportunity to take charge of their health by offering services and products that will help them manage their disease better. Holistic management of the disease starting form prevention, detection and treatment is key to reducing to the incidence of diabetes in India.”

Since its inception in 2014, Medlife has fast grown into a leading health tech company, catering to the needs of its consumers through affordable, convenient and holistic healthcare solutions. With diabetes at the forefront of lifestyle diseases in India, Medlife is committed to reducing the burden of the disease by innovating a range of products and services for diabetes.

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

8 hours ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

1 day ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

4 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

5 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

6 days ago